• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Femasys Inc.

    4/28/25 4:40:12 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email
    DEFA14A 1 ef20048051_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     Washington, D.C. 20549
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

    Filed by the Registrant ☒
    Filed by a party other than the Registrant   ☐
    Check the appropriate box:
     
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☒
    Definitive Additional Materials
    ☐
    Soliciting Material under §240.14a-12
     
    FEMASYS INC.
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     
    Payment of Filing Fee (Check the appropriate box):

    ☒
    No fee required

    ☐
    Fee paid previously with preliminary materials

    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
     


    Your Vote Counts! BROADRIDGE CORPORATE ISSUER SOLUTIONS C/O FEMASYS INC. P.O. BOX 1342 BRENTWOOD, NY 11717 FEMASYS INC. 2025 Annual Meeting Vote by June 24, 2025 11:59 P.M. EDT Vote in Person at the Meeting* June 25, 2025 9:00 AM EDT Offices at Femasys Inc. 3950 Johns Creek Court, Suite 100 Suwanee, Georgia 30024 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V74720-P31331 You invested in FEMASYS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 25, 2025. Get informed before you vote View the Notice & Proxy Statement for the Annual Meeting of Stockholders and our Annual Report on Form 10-K for the year ended December 31, 2024 are available online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 11, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends1.Election of Directors Nominees:1a.Alistair Milnes For 1b.Edward Uzialko, Jr. For 2.To approve an amendment to the Femasys Inc. 2021 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2021 Plan by 3,000,000 shares. For 3.To ratify the appointment of KPMG LLP as the independent registered public accounting firm. For 4. To transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.
     


    Get the next $FEMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Elefant Dov

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:39 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Currie Daniel Scott increased direct ownership by 29% to 86,275 units (SEC Form 4)

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:42 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Larsen Charles

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:45 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

      -- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces a partnership with Carolinas Fertility Institute (CFI), one of America's best fertility clinics. Carolinas Fertility Institute will provide the Company's FemaSeed® intratubal insemination product as an infertility treatment option to patients throughout its network in North Carolina. "Our partnership

      6/11/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

      ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gros

      5/30/25 8:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      6/17/25 9:22:13 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form D filed by Femasys Inc.

      D - FEMASYS INC (0001339005) (Filer)

      6/10/25 1:30:16 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      6/2/25 7:29:23 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care